Experiments with two KRAS G12C inhibition‐sensitive CDX models Mia PaCa‐2 (Pancreatic cancer) and NCI‐H358 (NSCLC) were used to evaluate the potential therapeutic utility of the AMG510‐IN10018 combination. This evidence concerns the gene KRAS and familial pancreatic carcinoma.